A 'game-changer' in the fight against obesity: Weekly jab can suppress your appetite and boost weight loss FIVE-fold, study reveals

• The drug semaglutide is sold under the brand names Ozempicand Rybelsus 
• 35% of people who took the drug lost more than one-fifth of their body weight
• 75% of those on semaglutide lost more than 10 per cent of their body weight
• Compared to the control group the reduction in BMI wa five times higher for people using A drug used to treat type 2 diabetes is also effective at helping obese people lose weight, a landmark study had found. 

  The drug semaglutide, sold under the brand names Ozempic and Rybelsus, was trialled on almost 2,000 obese adults around the world. 

  More than one third of people who took the drug lost a fifth of their total body weight while the majority (75 per cent) lost at least one tenth of their body weight.semaglutide

Researchers say the findings are a game-changer because weight loss can be achieved in people who would otherwise require surgery. 

Scroll down for video 



+2

The drug semaglutide, sold under the brand names Ozempicand Rybelsus, was given to adults with an average BMI of 38.  More than one third (35 per cent) of people who took the drug lost more than one-fifth of their total body weight.

Being fat can PROTECT you from certain diseases 

We're regularly told to minimise the amount of saturated fats we consume, but a new study suggests that eating foods rich in these fats could actually offer some protection against certain diseases.

Researchers have revealed that eating foods rich in saturated fats, including cakes, bacon and cheese, may reduce your risk of acute pancreatitis.

The US team analysed data from people in 11 countries on how different fats consumed by different nations – either unsaturated or saturated – are linked with the serious condition, where the pancreas becomes inflamed.  

Saturated fat is found in butter, lard, fatty meats and cheese – foods heavily consumed in western societies – while unsaturated fats are mostly found in oils from plants and fish and are prevalent in Asian and some South American diets. 

The scientists found that high levels of unsaturated fat stored around the abdominal organs generates more of a certain type of molecule that triggers cell injury, inflammation and even organ failure.   

Official advice from the NHS is to swap saturated fats for unsaturated fats in our diet to reduce the risk of heart disease. 

While this study does not challenge this advice, it does suggest obesity can sometimes protect patients during certain types of acute illnesses.

This 'obesity paradox' has already been controversially suggested in previous studies, but not without backlash from other experts.

Average weight loss in people taking semaglutide was 15.3kg (2.4 stone), whereas participants in the placebo group lost just 2.6kg (0.4 stone).

The findings of this study, called STEP-1, are being hailed for their potential to improve the health of people with obesity.

They could play a major part in helping the UK to reduce the impact of diseases, such as Covid-19, experts suggest.

Semaglutide is already approved for use in humans but is normally prescribed to diabetics with a 1mg dose. 

A 2.4mg dose, administered weekly as a subcutaneous jab, much like an insulin injection, was used in the STEP-1 study. 

Novo Nordisk, the manufacturer of semaglutide, bankrolled the study and says the weight-loss drug will soon be submitted for regulatory approval as a treatment for obesity to NICE.  

Approval is expected before the end of the year.  

The drug works by hijacking the body's own appetite regulating system in the brain, leading to reduced hunger and calorie intake. 

Rachel Batterham, professor of obesity, diabetes and endocrinology at UCL, who lead the research, said: 'The findings of this study represent a major breakthrough for improving the health of people with obesity.

'No other drug has come close to producing this level of weight loss - this really is a gamechanger.

'For the first time, people can achieve through drugs what was only possible through weight-loss surgery.'

Professor Batterham added that the drug could have major implications for UK health policy for years to come.

Weight loss was also accompanied by reductions in waist circumference, blood fats, blood sugar and blood pressure.

The trial's UK chief investigator, Professor John Wilding from the University of Liverpool, said: 'This is a significant advance in the treatment of obesity.

'Semaglutide is already approved and used clinically at a lower dose for treatment of diabetes, so as doctors we are already familiar with its use.'

People taking part in the study either received the drug or a placebo and also had access to individual face-to-face or phone counselling sessions from registered dietitians every four weeks as well as getting guidance to help with behavioural strategies and motivation.

Additionally, participants received incentives such as kettlebells or food scales to mark progress and milestones. 

Pinder Sahota, General Manager of Novo Nordisk UK, said: 'The findings of the STEP 1 study demonstrate the clinical value of semaglutide 2.4 mg for people living with obesity in the UK.

'Semaglutide 2.4mg is currently going through approval as one of the first medicines in the MHRA's accelerated assessment pathway – which aims to bring treatment to patients faster. 

'Novo Nordisk expect approval for semaglutide 2.4 mg by the end of the year.



+2

Of those taking semaglutide, the average weight loss was 15.3kg, with a reduction in BMI of minus 5.54. The placebo group observed an average weight loss of 2.6kg (0.4 stone) with a reduction in BMI of minus 0.92, more than five times less than those using the drug

'At Novo Nordisk we have committed decades of research to defeating diabetes, obesity, rare blood and endocrine disorders, to improve the lives of millions of people affected by these conditions in the UK. 

'These positive results published in the NEJM show the potential of semaglutide 2.4 mg as a new treatment option, as an adjunct to diet and exercise, for people living with obesity to support their weight loss and health goals.'

Some participants reported side effects from the drug including mild-to-moderate nausea and diarrhoea that were transient and generally resolved without permanent discontinuation from the study. 

Dr Baptiste Leurent from the London School of Hygiene and Tropical Medicine, who was not involved in the study, says this will need close monitoring. 

'We also need to better understand what is happening once the treatment is stopped, and whether it could be taken for a shorter period of time,' he adds. 

Dr Amelia Hollywood, a health psychologist from the University of Reading, adds: 'It is promising to hear that there is another potential weight loss medication that can be offered to patients, as currently the only one that has proved to be safe and effective is orlistat. 

'This will be good news for clinicians and patients. However it is worth noting that individuals did not just simply inject this medication and lose weight, they also had to change their behaviour.'

OBESITY: ADULTS WITH A BMI OVER 30 ARE SEEN AS OBESE

Obesity is defined as an adult having a BMI of 30 or over.

A healthy person's BMI - calculated by dividing weight in kg by height in metres, and the answer by the height again - is between 18.5 and 24.9. 

Among children, obesity is defined as being in the 95th percentile.

Percentiles compare youngsters to others their same age. 

For example, if a three-month-old is in the 40th percentile for weight, that means that 40 per cent of three-month-olds weigh the same or less than that baby.

Around 58 per cent of women and 68 per cent of men in the UK are overweight or obese. 

The condition costs the NHS around £6.1billion, out of its approximate £124.7 billion budget, every year.

This is due to obesity increasing a person's risk of a number of life-threatening conditions.

Such conditions include type 2 diabetes, which can cause kidney disease, blindness and even limb amputations.

Research suggests that at least one in six hospital beds in the UK are taken up by a diabetes patient.

Obesity also raises the risk of heart disease, which kills 315,000 people every year in the UK - making it the number one cause of death.

Carrying dangerous amounts of weight has also been linked to 12 different cancers. 

This includes breast, which affects one in eight women at some point in their lives.

Among children, research suggests that 70 per cent of obese youngsters have high blood pressure or raised cholesterol, which puts them at risk of heart disease.

Obese children are also significantly more likely to become obese adults. 

And if children are overweight, their obesity in adulthood is often more severe.  

As many as one in five children start school in the UK being overweight or obese, which rises to one in three by the time they turn 10.  

•